Nanoparticles in Nanomedicine Application: Lipid-Based Nanoparticles and Their Safety Concerns

  • Rabiatul Basria S. M. N. MydinEmail author
  • Said Moshawih


The ability to control particle size and shape in engineering materials, paved the way for introducing nanostructures with unique properties and broad applications. The small size of nanostructures gives rise to more toxic reactions due to a higher surface area relative to volume and this in turn changes absorption, distribution, metabolism and excretion of nanoparticles (NPs). This also enhances cellular uptake and thus increases the interference with the biological milieu due to large surface area and surface functionalization. Notably, NPs are either degradable nanoparticles such as dendrimers, which can produce unexpected toxic byproducts, or non-degradable ones such as metallic NPs that accumulate in tissues and cells and consequently lead to pernicious effects. The uniqueness of each type of organic and inorganic NPs in addition to the route of administration make their behavior in biological systems more complicated than expected, thus, in vivo and in vitro studies are strongly recommended.



The authors are thankful to the Ministry of Education (MOE) Malaysia for funding this work under Transdisciplinary Research Grant Scheme (TRGS) grant no. 6769003 and Universiti Sains Malaysia (USM) for USM-Short Term Research Grant (304/CIPPT/6315073).


  1. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59:454–477CrossRefPubMedGoogle Scholar
  2. Dobrovolskaia MA, Patri AK, Potter TM, Rodriguez JC, Hall JB, Mcneil SE (2012) Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine 7:245–256CrossRefPubMedGoogle Scholar
  3. Graf A, McDowell A, Rades T (2009) Poly (alkycyanoacrylate) nanoparticles for enhanced delivery of therapeutics—is there real potential? Expert Opin Drug Deliv 6:371–387CrossRefPubMedGoogle Scholar
  4. Greish K, Thiagarajan G, Herd H, Price R, Bauer H, Hubbard D, Burckle A, Sadekar S, Yu T, Anwar A (2012) Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 6:713–723CrossRefPubMedGoogle Scholar
  5. Ilinskaya AN, Dobrovolskaia MA (2013) Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine 8:969–981CrossRefPubMedGoogle Scholar
  6. Inoue KI (2011) Promoting effects of nanoparticles/materials on sensitive lung inflammatory diseases. Environ Health Prev Med 16:139–143CrossRefPubMedGoogle Scholar
  7. Juliano R, Hsu M, Peterson D, Regen S, Singh A (1983) Interactions of conventional or photopolymerized liposomes with platelets in vitro. Exp Cell Res 146:422–427CrossRefPubMedGoogle Scholar
  8. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener J, Meijer E, Paulus W, Duncan R (2000) Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 65:133–148CrossRefPubMedGoogle Scholar
  9. Mcguinnes C, Duffin R, Brown S, Mills NL, Megson IL, Macnee W, Johnston S, Lu SL, Tran L, Li R (2010) Surface derivatization state of polystyrene latex nanoparticles determines both their potency and their mechanism of causing human platelet aggregation in vitro. Toxicol Sci 119:359–368CrossRefPubMedGoogle Scholar
  10. Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W (1997) Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 14:458–462CrossRefPubMedGoogle Scholar
  11. Nadziejko, C., Fang, K., Chen, L., Cohen, B., Karpatkin, M. & Nadas, A. 2002. Effect of concentrated ambient particulate matter on blood coagulation parameters in rats. Research report (Health Effects Institute), 7–29; discussion 31–8Google Scholar
  12. Nemmar A, Hoylaerts MF, Hoet PH, Vermylen J, Nemery B (2003) Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol 186:38–45CrossRefPubMedGoogle Scholar
  13. Saiyed M, Patel R, Patel S (2011) Toxicology perspective of nanopharmaceuticals: a critical review. Int J Pharm Sci Nanotechnol 4:1287–1295Google Scholar
  14. Schöler N, Zimmermann E, Katzfey U, Hahn H, Müller R, Liesenfeld O (2000) Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J Microencapsul 17:639–650CrossRefPubMedGoogle Scholar
  15. Stasko NA, Johnson CB, Schoenfisch MH, Johnson TA, Holmuhamedov EL (2007) Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules 8:3853–3859CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Rabiatul Basria S. M. N. Mydin
    • 1
    Email author
  • Said Moshawih
    • 2
  1. 1.Oncological and Radiological Sciences Cluster, Advanced Medical and Dental InstituteUniversiti Sains MalaysiaKepala BatasMalaysia
  2. 2.Jordan Center for Pharmaceutical ResearchAmmanJordan

Personalised recommendations